The roles of peroxisome proliferator-activated receptor (PPAR)-d in vascular biology are mainly unknown. We investigated the effects of PPAR-d activation on the paracrine networks between endothelial progenitor cells (EPCs) and endothelial cells (ECs)/skeletal muscle.
Introduction
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor superfamily. Among the three subtypes of PPARs, PPAR-d is the least understood. Peroxisome proliferatoractivated receptor-d has been shown to perform key roles in lipid homeostasis, carbohydrate metabolism, and energy expenditure. 1 However, the roles of PPAR-d in vascular biology remain largely unexplored. We showed that PPAR-d activation directly modulates 'early' endothelial progenitor cells (EPCs), and leads to enhanced † First three authors equally contributed to this work. 'vasculogenesis'. 2 Another group showed the pro-vasculogenic effects of PPAR-d on 'late' EPCs. 3 Recent studies have demonstrated that PPAR-d activation inhibits apoptosis of endothelial cells (ECs) 4 and promotes 'angiogenesis' through direct effects on ECs. 5 But in 'real-world' clinical settings, neovascularization alone does not suffice for the treatment of vascular diseases. For example, limb ischaemia is the complicated process where several components such as EPCs, ECs, and skeletal muscle should be involved. Naturally, we need to pay attention to the relationship among these components.
Insulin-like growth factor-1 (IGF-1) is a potent mitogen that induces angiogenesis 6 and skeletal muscle regeneration. 7 Six plasma IGF-1-binding proteins (IGFBPs) (IGFBP-1 to IGFBP-6) modulate the biological effects of IGF-1, which sequestrate IGF-1 and inhibit the interaction between IGF-1 and IGF-1 receptor (IGF-1R). 8 Among IGFBPs, IGFBP-3 is the most abundant in human plasma. 9 Proteolysis of IGFBPs by several proteases can release IGF-1 from the complex and activate IGF-IR. 10 Matrix metallo-proteinases (MMPs) are zinc-dependent proteinases, responsible for proteolytic processing of the extracellular matrix and associated with mechanisms of angiogenesis and cell migration. 11 Matrix metallo-proteinases also cleave various regulatory molecules and activate growth factors and cytokines. 12 Matrix metallo-proteinases-1,-2,-3,-7, and -9 have been known to degrade IGFBP-3. 10, 13, 14 Among these, MMP-9 is known to be the most abundantly secreted from 'early' EPCs. 15 Based on the above facts, we supposed that the paracrine networks could exist between 'early' EPCs and ECs/skeletal myocytes linked through MMP-9-mediated IGFBP-3 degradation. In this study, we found that PPAR-d activation significantly increased MMP-9 secretion from EPCs through direct transcriptional regulation. Subsequently, we assessed the potential in vitro effects of MMP-9 from PPAR-d-activated EPCs on the IGF-1-signalling pathway in ECs and skeletal myocytes. Ultimately, we revealed its in vivo effects on angiogenesis and muscle regeneration.
Methods Early endothelial progenitor cells culture
The protocol for use of human blood samples was approved by the Institutional Review Board at the Seoul National University Hospital. Early EPCs were isolated following our established protocol. 15 Briefly, mononuclear cells (MNCs) were isolated from healthy volunteers' blood using Ficoll. 15 1 × 10 7 MNCs/well were seeded on 2% fibronectin-coated (Sigma) six-well plates and cultured using EGM-2MV BulletKit system (Clonetics) consisting of endothelial basal medium, 5% FBS, human EGF, VEGF, human FGF-B, IGF-1, ascorbic acid, and heparin in a 5% CO 2 incubator at 378C. First media change was performed 5 days after plating, and thereafter, media were changed every 3 days. In accordance with the status of cells, 7 -10 days cultured early EPCs were used for experiments. Endothelial progenitor cell designates 'early' EPC hereafter. 
Statistical analysis

Results
Peroxisome proliferator-activated receptor-d activation in endothelial progenitor cells specifically increases matrix metallo-proteinase-9 expression, secretion, and its activity
We screened the mRNA change of several types of MMPs and tissue inhibitor of metallo-proteinases (TIMPs) by PPAR-d activation in EPCs. Among these, only MMP-9 mRNA expression was significantly up-regulated in EPC cells after a 24 h-treatment with GW501516 (1 mM), a potent and highly specific PPAR-d agonist 16 ( Figure 1A) . The mRNA expression of other MMPs (MMP-1,-2,-3,-7, and -14), TIMP-1, and TIMP-2 did not change on GW501516 treatment ( Figure 1A ). The secretion of MMP-9 protein into culture medium was assessed by western blot assays using conditioned medium (CM). It demonstrated that GW501516 treatment (1 mM) significantly increased MMP-9 secretion from EPCs ( Figure 1B ). The gelatinolytic activity by MMP-9 also increased after GW501516 treatment (1 mM) ( Figure 1C) . However, the secretion and gelatinolytic activity of MMP-2 which is another major MMP from EPCs 15 did not change ( Figure 1B and C ). We also evaluated the effects of PPAR-d activation on MMP-9 expression in the other cells constituting the important components in the environment of peripheral vascular disease, such as late EPCs, 15 ECs, and C2C12 cells. C2C12
is a mouse myoblast cell line which differentiates rapidly, forms contractile myotubes, and produces characteristic muscle proteins. 17 Intriguingly, in these other cells, there was no significant change in MMP-9 mRNA expression, its protein secretion into culture medium, and the enzymatic activity of secreted MMP-9 after GW501516 treatment (Supplementary material online, Figure S1 ). Accordingly, we focused on PPAR-d-mediated MMP-9 regulation in EPCs thereafter.
Peroxisome proliferator-activated receptor-d activation in endothelial progenitor cells induces matrix metallo-proteinase-9 expression through direct transcriptional activation
After activated by ligands, PPAR-d, acting as a transcription factor, binds to the promoters of target genes that contain peroxisome proliferator-activated receptor response elements (PPREs). A PPRE is a direct repeat of the consensus sequence, AGGTCA, separated by any single nucleotide (AGGTCANAGGTCA). 18 Analysis of the human MMP-9 promoter region identified 3 putative PPREs located at 21972 (76.9%), 2245 (69.2%) and 274 (69.2%) (% denotes homology to consensus sequence) (Supplementary material online, Figure S2 ). Chromatin immunoprecipitation assays using EPCs treated with GW501516 (1 mM) for 5 h verified in vivo binding of PPAR-d to each three putative PPREs in a liganddependent manner ( Figure 1D ). To determine whether three putative PPREs actually function for MMP-9 promoter activity, luciferase promoter assays using sequential 5 ′ -deletion mutations of the promoter were performed. GW501516 treatment (1 mM) significantly increased the full-length promoter activity. After sequential deletion of the putative PPREs, the PPAR-d-mediated MMP-9 promoter activity decreased in order of precedence ( Figure 1E ). After deletion of all PPREs, the response to GW501516 treatment was totally abolished. These data suggested that PPAR-d activation induced MMP-9 expression through direct transcriptional activation. 
PPAR-d activates EPCs, inducing angio-myogenesis
Peroxisome proliferator-activated receptor-d activation in endothelial progenitor cells enhances matrix metallo-proteinase-9-mediated insulin-like growth factor-binding protein-3 proteolysis, leading to insulin-like growth factor-1R phosphorylation in target cells via a paracrine manner
To evaluate the possibility that the enhanced MMP-9 expression by PPAR-d activation affects the IGF-1-signalling pathway, we determined whether MMP-9 in the CM from EPCs could degrade IGFBP-3 and led to activation of the IGF-1 receptor in surrounding target cells via a paracrine manner. Conditioned medium from EPCs treated for 72 h with GW501516 (1 mM) or vehicle was harvested and incubated with recombinant human (rh) IGFBP-3 (1 mg/mL). Conditioned medium from GW501516-treated EPCs more extensively degraded rhIGFBP-3 compared with that from vehicle-treated EPCs ( Figure 2A ). For more clarification of the effect of MMP-9 on IGFBP-3 degradation, MMP-9 was selectively collected from the CM of GW501516-treated EPCs by immunoprecipitation. The purified MMP-9 effectively degraded rhIGFBP-3 ( Figure 2B ). After IGFBP-3 is degraded, IGF-1 is released from IGFBP-3 and may result in IGF-1R activation in the surrounding cells. To Figure 2 Matrix metallo-proteinase in the conditioned media from peroxisome proliferator-activated receptor-d-activated endothelial progenitor cells degraded rhinsulin-like growth factor-binding protein-3, resulting in the activation of insulin-like growth factor-1R in endothelial cells. (A) Western blot assays for rhinsulin-like growth factor-binding protein-3 after incubation with the conditioned medium from GW501516-treated-(1 mM) (GW-CM) or vehicle-treated endothelial progenitor cells (vehicle-conditioned medium). The 46 kDa band indicates intact rhinsulin-like growth factor-binding protein-3, and the lower bands indicate its proteolytic fragments. (B) rhinsulin-like growth factor-binding protein-3 degradation by matrix metallo-proteinase-9 protein purified using immunoprecipitation from GW-CM. (C ) Phosphorylated insulin-like growth factor-1R in human umbilical vein endothelial cells after GW-CM treatment. Total insulin-like growth factor-1R was used as an internal control. GM indicates GM6001. GM6001 reversed degradation of insulin-like growth factor-binding protein-3 and activation of insulin-like growth factor-1R, which were induced by peroxisome proliferator-activated receptor-d activation, n ¼ 3 in (A -C). All these immunoblot assays were performed in triplicate and each representative figure is shown. 
Peroxisome proliferator-activated receptor-d-activation in endothelial progenitor cells up-regulates the number and the angiogenic functions of endothelial cells through matrix metallo-proteinase-9-mediated insulin-like growth factor-1R activation Then, we evaluated the in vitro effects of MMP-9-mediated IGF-1R activation in surrounding ECs. Conditioned medium from GW501516 (1 mM)-or vehicle-treated EPCs was incubated with a mixture of IGF-1 and rhIGFBP-3. Then we treated the resultant CM to HUVECs for the following bioassays. In a BrdU incorporation assay, CM from GW501516-treated EPCs significantly increased BrdU incorporation into HUVECs, indicating enhanced proliferation of ECs ( Figure 3A) . It also enhanced the angiogenic functions of ECs. It induced a strong migratory response of HUVECs in a scratch wound migration assay ( Figure 3B ) and augmented in vitro capillary formation by HUVECs in a Matrigel tube formation assay ( Figure 3C) . Pretreatment of the mixture with MMP inhibitor GM6001 (10 mM) or IGF-1R neutralizing antibody (aIR3) (1 mg/mL) reversed all these effects, showing their dependence on MMP and IGF-1R ( Figure 3A-C) .
Peroxisome proliferator-activated receptor-d-activated endothelial progenitor cells induce proliferation and enhance viability of skeletal myocytes
As another important surrounding target cell, skeletal myocytes were selected because skeletal muscle regeneration is also an important component in peripheral vascular diseases. In a BrdU incorporation assay, CM from GW501516-treated EPCs increased the proliferation of C2C12 cells compared with that from vehicletreated EPCs ( Figure 3D) . In a WST-1 assay performed under serumstarvation condition, it enhanced the survival of C2C12 cells ( Figure 3E ). These proliferating and pro-survival effects were also dependent on MMP and IGF-1R ( Figure 3D and E).
GSK0660 ( Systemic administration of peroxisome proliferator-activated receptor-d agonist increases matrix metallo-proteinase-9 production from endothelial progenitor cells in vivo and results in the enhanced serum insulin-like growth factor-binding protein-3 proteolysis in mice
To investigate the in vivo effect of PPAR-d agonist on MMP-9 in EPCs, GW501516 (10 mg/kg/day) was intraperitoneally (i.p.) injected to wild-type (WT) or MMP-9 KO mice. After 1 week of daily systemic administration, mouse EPCs were cultured from bone marrow (BM) MNCs and spleen MNCs were also isolated. A western blot assay showed augmented MMP-9 protein production in BM-derived EPCs and spleen MNCs of GW501516-treated WT mice ( Figure 4A) . No MMP-9 production was observed in MMP-9 KO mice regardless of GW501516 administration. Sera were isolated from the whole blood of the same mice. Immunoprecipitation and subsequent immunoblot assay showed the enhanced degradation of IGFBP-3 in the sera of GW501516-treated WT mice ( Figure 4B ). This effect was not observed in MMP-9 KO mice, showing its dependence on MMP-9 activity.
Systemic administration of peroxisome proliferator-activated receptor-d agonist activates the insulin-like growth factor-1R in endothelial cells and skeletal muscle of the mouse ischaemic hindlimb
To determine the in vivo effects of PPAR-d activation in EPCs on the IGF-1-signalling pathway of ECs and skeletal muscle, we performed a mouse hindlimb ischaemia model after bone marrow Figure 4 Systemic administration of peroxisome proliferatoractivated receptor-d agonist in mice increased matrix metallo-proteinase-9 protein expression in bone marrow-derived endothelial progenitor cells and enhanced degradation of insulinlike growth factor-binding protein-3 in sera. (A) Matrix metallo-proteinase-9 protein expression in bone marrow-derived endothelial progenitor cells and spleen mononuclear cells after systemic administration of GW501516 in wild-type or matrix metallo-proteinase-9 knock-out mice. (B) Western blot assays of mice sera for insulin-like growth factor-binding protein-3. The 46 kDa band indicates intact insulin-like growth factorbinding protein-3, and the lower bands indicate its proteolytic fragments. Peroxisome proliferator-activated receptor-d agonist induced matrix metallo-proteinase-9 expression and insulin-like growth factor-binding protein-3 degradation, which were not observed in matrix metallo-proteinase-9 knock-out mice. GW indicates GW501516, n ¼ 6 in each group. Each representative figure is shown.
transplantation (BMT). Wild-type mice received BMT from WT or MMP-9 KO mice. After 4 weeks of engraftment, left femoral arteries of the recipient mice were excised. From 2 days before to 7 days after the operation, GW501516 (10 mg/kg/day) or vehicle was continuously infused through i.p. pump. To confirm the role of IGF-1-signalling pathway, IGFBP-3 (60 mg/ kg/h) was infused together with GW501516 in some mice. An immunofluorescent staining of the ischaemic skeletal muscle on Day 7 showed significantly enhanced IGF-1R phosphorylation in ECs of capillaries in GW501516-treated WT/WT (donor/recipient) mice ( Figure 5) . Furthermore, GW501516-treated WT/ WT mice (WT/WT/GW) showed stronger diffuse fluorescence over the skeletal muscle, showing that PPAR-d agonist also induced IGF-1R activation in skeletal muscle. In contrast, IGF-1R phosphorylation was not evident in both ECs and skeletal muscle regardless of GW501516 treatment in KO/WT mice, demonstrating that the phosphorylation was mainly dependent on MMP-9 from BM-derived cells. Insulin-like growth factor-binding protein-3 infusion inhibited the phosphorylation of IGF-1R in WT/WT mice receiving GW501516 treatment (WT/WT/GW + BP3).
Systemic administration of peroxisome proliferator-activated receptor-d agonist increases regenerating myotubes in skeletal muscle of a mouse ischaemic hindlimb
To assess the ultimate effects of PPAR-d activation in EPCs on in vivo angio-myogenesis, GW501516 (10 mg/kg/day) was systemically administered through peritoneum for 2 weeks in another mouse ischaemic hindlimb model with BMT from WT or MMP-9 KO mice. Subsequently to IGF-1R activation, skeletal muscle regeneration occurred. GW501516 treatment for 2 weeks increased the Figure  S5A and B). Interestingly, the total IGF-1R expression, including unphosphorylated and phosphorylated forms was mainly observed in regenerating myotubes, highlighting the importance of the IGF-1-signalling pathway in regenerating skeletal muscle (Supplementary material online, Figure S5C ).
Systemic administration of peroxisome proliferator-activated receptor-d agonist promotes angiogenesis and eventually protects skeletal muscle from ischaemic damage in a mouse ischaemic hindlimb
Serial examinations using laser Doppler perfusion imager revealed that the blood flow recovered more rapidly in the ischaemic limbs of GW501516-treated WT/WT mice. However, it was not improved by GW501516 administration in KO/WT mice (Supplementary material online, Figure S5D and E). The capillaries in the ischaemic muscle were identified by CD31 immunofluorescent staining, and then their number was normalized by skeletal myocytes. The capillary-to-myocyte ratio was significantly higher in GW501516-treated WT/WT mice than vehicle-treated mice. In KO/WT mice, fewer capillaries were observed regardless of GW501516 treatment (Supplementary material online, Figure S5F and G). The proliferation of ECs and skeletal myocytes by PPAR-d activation in this model was verified by Ki-67 immunostaining (Supplementary material online, Figure S6A -D) , whereas the decrease of their apoptosis was shown by TUNEL staining (Supplementary material online, Figure S6E -H). The neovascularization through this EPC paracrine networks potentiated by PPAR-d was mainly angiogenesis, not arteriogenesis (Supplementary material online, Figure S7 ). Enhanced muscle regeneration and increased angiogenesis by PPAR-d agonist administration ultimately protected an ischaemic limb from hypoxic damage. In Masson's trichrome stain, muscle architecture was preserved more intact and fibrosis was not observed in GW501516-treated WT/WT mice (Supplementary material online, Figure S5H ). Insulin-like growth factor-binding protein-3 infusion reversed the above effects of PPAR-d agonist, demonstrating that IGF-1R activation was required for the angiomyogenic action of PPAR-d activation (Supplementary material online, Figures S5A and B, D-H, S6A-H) .
Transplantation of ex vivo peroxisome proliferator-activated receptor-d-activated endothelial progenitor cells to ischaemic limb activates the insulin-like growth factor-1R, and induces angio-myogenesis
To confirm the specific role of EPCs in PPAR-d-induced angiomyogenesis, PPAR-d-activated EPCs were transplanted to ischaemic hindlimbs of athymic nude mice. Endothelial progenitor cells were isolated from WT or MMP-9 KO mice, then injected to ischaemic hindlimbs after 3 days ex vivo treatment of GW501516 (1 mM). Like systemic administration of GW501516, transplantation of GW501516-treated WT EPCs increased IGF-1R phosphorylation in ECs and skeletal muscle 1 week after the transplantation (Supplementary material online, Figure S8 ). It induced muscle regeneration, and enhanced limb perfusion and capillary density after 2 weeks (Supplementary material online, Figure S9A -F) . This resulted in skeletal muscle preservation (Supplementary material online, Figure S9G) . The above effects of ex vivo PPAR-d activation were not observed in MMP-9 KO EPCs transplanted mice (Supplementary material online, Figure S9A -G).
Systemic administration of peroxisome proliferator-activated receptor-d agonist promotes rapid wound healing with angiogenesis in a mouse skin punch wound model
To confirm the effects of PPAR-d activation on angiogenesis, we used another in vivo model where angiogenesis plays a significant role, a mouse skin punch wound model. From 2 days before to 7 days after making 8-mm sized circular skin punch wounds in the back (n ¼ 10 in each group), WT and MMP-9 KO mice received daily i.p. injection of GW501516 (10 mg/kg/day) or vehicle. GW501516 systemic administration induced rapid wound closure in WT mice (Supplementary material online, Figure S10A and B). It also increased MMP-9 protein expression in the skin wounds of WT mice (Supplementary material online, Figure S1C ). Immunofluoroscent staining of wound sections showed that GW501516 injections significantly enhanced IGF-1R phosphorylation in capillary ECs (Supplementary material online, Figure S1D ). In H&E staining, more capillaries containing red blood cells were observed in the skin wounds of WT mice that received GW501516, demonstrating enhanced angiogenesis (Supplementary material online, Figure S10E and F ). All these effects were not observed in MMP-9 KO mice (Supplementary material online, Figure S10A -F).
Discussion
Neovascularization is generally classified as vasculogenesis by EPCs and angiogenesis by pre-existing ECs. In the previous study, we found that PPAR-d directly regulates the number and functions of EPCs through the Akt pathway and induces vasculogenesis ( Figure 6A) . 2 In contrast, in this study, we elucidated the role of PPAR-d in the paracrine networks between EPCs and ECs or skeletal muscle cells, leading to angio-myogenesis ( Figure 6B and C ). Until now, the studies on EPCs have focused on neovascularization. Moreover, although the contribution of BM-derived cells to skeletal muscle regeneration was reported, the transdifferentiation of BM-derived stem cells into skeletal myocytes was suggested as a main mechanism. 20, 21 24 /endothelial colony-forming cells. 25 Recently, much attention is paid to paracrine effects rather than direct incorporation into endothelial monolayer to explain the mechanism of neovascularization by 'early' EPCs. In this regard, our study provides new evidence supporting the role of 'early' EPC as a key player in angio-myogenic paracrine networks.
Interestingly, though PPAR-d is expressed also in ECs and skeletal muscle, 4, 5, 26 the extent of MMP-9 up-regulation by PPAR-d activation in ECs and C2C12 cells was negligible. Furthermore, the basal expression level of MMP-9 in these cell types was minimal compared with EPCs. Therefore, in the setting of EPCmediated angio-myogenesis where EPCs, ECs, and skeletal myocytes take part, MMP-9-mediated IGF-1 pathway activation by PPAR-d is considered to be specific to EPCs. Peroxisome proliferator-activated receptor-d activation also induces matrix metallo-proteinase-9 secretion from endothelial progenitor cells, leading to insulin-like growth factor-binding protein-3 degradation in serum. Then, the free insulin-like growth factor-1 can activate insulinlike growth factor-1R in the surrounding endothelial cells and skeletal muscle. These potentiated paracrine networks induce angiogenesis (B) and muscle regeneration (C). Figure S11A and B) . Therefore, the effects of PPAR-d activation on paracrine networks of EPCs are mainly attributable to MMP-9. The secretion of MMP-9 is known to be induced by various cytokines, such as SDF-1, 28 TNF-a, and TGF-b. 29 However, the modulation of MMP-9 by PPAR-d activation in EPCs has not been reported. In this study, we showed for the first time that PPAR-d activation increased MMP-9 expression and activity in EPCs through direct regulation at the transcription level. Interestingly, we found that IGF-1 receptors were predominantly expressed in regenerating skeletal myotubes. Although it is known that IGF-1 plays a crucial role in skeletal muscle regeneration, 7 the difference in the pattern of expression of IGF-1R between mature myocytes and regenerating myotubes has not been reported. While much remains to be learned about the regulation of the IGF-IR expression in regenerating myotubes, our results highlight the significance of the IGF-1 pathway in skeletal muscle regeneration. Recently a few studies demonstrated two different action mechanisms of IGFBP-3. Traditionally IGFBP-3 is a significant inhibitor of cell growth and enhancer of apoptosis via inhibition of the action of IGF-1. On the other hand, the direct positive effects of IGFBP-3 on vessel formation, independent of IGF-1/ IGF-1R axis, take a growing interest. 30 In order to clarify the controversy on the role and action mechanism of IGFBP-3 depending on the different situations, we adopted more physiological experimental design and treated HUVECs or C2C12 cells with both IGFBP-3 and IGF-1 in in vitro assays of this study. We believe that this experimental condition better reflects the in vivo physiological environment than IGFBP3 treatment alone, because 98% of IGF-1 is always bound to IGFBPs, and IGFBP-3 accounts for 75 -90% of circulating IGF-1 binding. 30 In our study, IGFBP-3 played a role of negative regulator in the PPAR-d -induced angiomyogenesis through inhibition of IGF-1 signalling. Peroxisome proliferator-activated receptor-d agonist treatment induced IGF-1R phosphorylation in vitro and in vivo experiments, and angiomyogenic effects of PPAR-d /MMP-9-mediated IGFBP3 degradation were reversed by IGF-1R neutralizing antibody. These findings suggest that the mechanism of angio-myogenic effect of IGFBP-3 degradation is mediated by IGF-1/IGF-1R axis in the environment of EPC-mediated angio-myogenesis. In this study, we used two different in vivo models: ischaemic limb and skin wound. With these models, we confirmed the pro-angio-myogenic effects of the PPAR-d agonist which was mediated by the paracrine networks between EPCs and ECs/skeletal muscle cells. Based on our results, we can reasonably expect a PPAR-d agonist to possess therapeutic potential in peripheral vascular diseases, including diabetic foot, in which not only new vessel formation, but also skin wound healing and/or muscle regeneration is essential in the treatment.
PPAR-d is widely expressed in various types of cells including
ECs, skeletal myocytes, and keratinocytes. Therefore, systemic administration of PPAR-d agonist may exert its direct effects on these cells and these effects may contribute to angiogenesis and skin wound healing. On the other hand, MMP-9-mediated IGF-1R activation may also occur in other types of cells on which we did not focus such as keratinocytes and smooth muscle cells. However, to reveal the effects of PPAR-d or IGF-1R activation on every type of cells existing in our in vivo models was beyond the scope of this study and may require further research.
In conclusion, our data suggest that EPCs are crucial players in angio-myogenic paracrine networks with ECs and skeletal muscle through MMP-9-mediated IGF-1-signalling pathway, and PPAR-d is a key molecule modulating the networks.
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